Literature DB >> 31471004

CRISPR-Cas9 gene editing for patients with haemoglobinopathies.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31471004     DOI： 10.1016/S2352-3026(19)30169-3

Source DB:  PubMed          Journal:  Lancet Haematol        ISSN： 2352-3026            Impact factor:   18.959


× No keyword cloud information.
  6 in total

Review 1.  CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases.

Authors:  Garima Sharma; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee; Chiranjib Chakraborty
Journal:  Mol Ther       Date:  2020-09-20       Impact factor: 11.454

Review 2.  CRISPR/Cas9 gene editing for curing sickle cell disease.

Authors:  So Hyun Park; Gang Bao
Journal:  Transfus Apher Sci       Date:  2021-01-10       Impact factor: 1.764

Review 3.  Translating genomic insights into cardiovascular medicine: Opportunities and challenges of CRISPR-Cas9.

Authors:  Yuan Zhang; Ioannis Karakikes
Journal:  Trends Cardiovasc Med       Date:  2020-06-27       Impact factor: 8.049

Review 4.  Mitochondrial Genome Editing to Treat Human Osteoarthritis-A Narrative Review.

Authors:  Gang Zhong; Henning Madry; Magali Cucchiarini
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

Review 5.  Variability in Genome Editing Outcomes: Challenges for Research Reproducibility and Clinical Safety.

Authors:  Lydia Teboul; Yann Herault; Sara Wells; Waseem Qasim; Guillaume Pavlovic
Journal:  Mol Ther       Date:  2020-03-20       Impact factor: 11.454

6.  From blood development to disease: a paradigm for clinical translation.

Authors:  Monica J Justice; Julija Hmeljak; Vijay G Sankaran; Merav Socolovsky; Leonard I Zon
Journal:  Dis Model Mech       Date:  2020-01-09       Impact factor: 5.758
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.